Better Buy: AST SpaceMobile or Rocket Lab?

AST SpaceMobile and Rocket Lab have market caps of $33B and $37B and are projected to trade at ~42x and ~31x their 2027 revenue, respectively. Rocket Lab has diversified near-term revenue paths, including a $190M hypersonic-test contract and an SDA satellite program worth up to $816M, while AST SpaceMobile relies on continued satellite launches to scale its space-based cellular broadband. Both stocks have rallied >1,500% over three years but face execution risks (AST constellation build; Rocket Lab Neutron delays and competition with SpaceX), leading the article to favor Rocket Lab as the better buy.

Analysis

The market has priced a large amount of optionality into both names, but the optionality is qualitatively different: one is mostly a multi-year consumer/adoption and regulatory bet built on unit-level economics and handset OEM wins; the other is a platform and services engineering bet with nearer-term government revenue waterfalls. That means shocks to consumer pricing, roaming economics or handset certification timelines will disproportionately compress implied value for the consumer-facing name, while schedule slips or a failed prototype test will more sharply impact the engineering-first name.

Second-order supply-chain effects matter: continued launch cadence de-risks manufacturing capacity and lowers marginal launch cost across the industry, benefiting vertically integrated launch providers and satellite assemblers while pressuring standalone constellation integrators that must subsidize service to acquire users. On the demand side, defense procurement budgets act as an asymmetric hedge for companies with established government relationships — they buy time and revenue predictability even if commercial adoption lags.

Time horizons diverge. Expect binary moves around test-flight and contract-conversion milestones over the next 3–18 months; structural revenue realization and ARPU visibility will play out over multiple years and require follow-on financing for high-capex constellation strategies. The biggest reversal risk is a sustained pricing response from a dominant incumbent that forces rapid margin compression across launch and connectivity services — that outcome crystallizes within 6–18 months if incumbents choose capacity-driven price competition.

Key Decisions for Investors

• Long RKLB (size 1–2% NAV): accumulate into weakness ahead of the next Neutron prototype milestones and upcoming government contract conversion points. Timeframe 12–24 months; target asymmetric upside of 40–80% if tests succeed and SDA contracts ramp. Place a tactical 25–30% stop-loss to protect against technical-development failure.
• Hedge/short ASTS via put spread (size 0.5–1% NAV): buy 12–18 month put spread to limit premium outlay (e.g., 30–50% OTM depending on current vols). Thesis: dilution/regulatory/handset-adoption risk could drive 40–60% downside; max loss = paid premium, max gain = spread width minus premium. Enter on volatility compression after a successful small launch or on an IV spike post-announcement.
• Pair trade — long RKLB / short ASTS dollar-neutral (size 1% NAV each leg): reduces macro beta while expressing conviction in engineering/government-backed revenue over consumer-adoption optionality. Rebalance on major milestones (Neutron test, SDA contract awards, constellation launch cadence); expect positive carry if government bookings convert and ASTS requires fresh capital.
• Tactical options: buy a 12-month RKLB call spread to cap cost and sell short-dated calls against part of the position post-success; for ASTS, prefer buying 9–18 month put spreads rather than naked puts to manage IV and limit skew exposure.